Caption Management’s ADMA Biologics ADMA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$8.37M Sell
1,000,000
-148,400
-13% -$1.35M 0.04% 441
2026
Q1
$10.3M Buy
1,148,400
+1,098,400
+2,197% +$17.3M 0.06% 328
2025
Q4
$912K Sell
50,000
-282,500
-85% -$4.76M 0.01% 1091
2025
Q3
$4.87M Buy
332,500
+35,000
+12% +$600K 0.04% 498
2025
Q2
$5.42M Buy
+297,500
New +$6.07M 0.06% 383

Other funds holding ADMA

Caption Management's ADMA Position: Q2 2026 in Review

Caption Management reduced its ADMA Biologics (ADMA) stake by 29% in Q2 2026, selling an estimated $1.73M and leaving 470,000 shares worth $3.93M. The position accounts for 0.02% of the portfolio, ranked #653.

Caption Management first reported a position in ADMA in Q2 2025 and has held it in 4 quarters since. The position peaked at $5.95M in Q1 2026. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Caption Management held 470,000 shares of ADMA Biologics worth $3.93M as of Q2 2026.
  • Caption Management sold 190,000 ADMA Biologics shares in Q2 2026, an estimated $1.73M.
  • ADMA Biologics made up 0.02% of Caption Management's portfolio in Q2 2026, its #653 holding.
  • Caption Management first reported a position in ADMA Biologics in Q2 2025 and has held it in 4 quarters since.
  • Caption Management's ADMA Biologics position peaked at $5.95M in Q1 2026.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.